Lachman Consultants Services, Inc. Announces Business Exposition Sponsorship of Access! 2019
While concluding its 40th Anniversary Celebration Year with the start of 2019, Lachman Consultants recently announced participation as Business Exposition Sponsor of ACCESS! 2019, the annual meeting of the Association for Accessible Medicines (AAM).
WESTBURY, N.Y., Jan. 22, 2019 /PRNewswire-PRWeb/ -- Lachman Consultant Services, Inc. a leading provider of expert compliance, regulatory affairs and technical services to life sciences clients worldwide will be a prominent participant at ACCESS! 2019, the annual gathering of the AAM. This year's event will take place from February 4th through 6th at the Hyatt Regency New Orleans, New Orleans, LA. Attendees are invited to visit with Lachman Consultants in Elite Hall "A" at Booths #21 and #26, directly across from the center main entrance.
Access! 2019 brings together policymakers, influential speakers and industry leaders to chart the future of generic and biosimilar medicines. Discussions center around the business, breakthroughs, and politics that shape the industry. With more than 50 exhibitors, valuable networking events and over 800 attendees, the sharing of information will be extremely valuable during the coming year. Scheduled to speak at the event are Nancy Snyderman, M.D., FACS, Physician and Former NBC News Chief Medical Editor, and Chester "Chip" Davis Jr., JD, President and CEO, AAM, as well as political icons James Carville and Mary Matlin.
A ROBUST PORTFOLIO OF GENERIC AND BIOSIMILAR SERVICES
Integral to its three main areas of service – Compliance, Regulatory Affairs, and Science & Technology – are Lachman's robust service capabilities for generics and biosimilars. Lachman Consultants is well-positioned to provide consultation and full development support for therapeutically equivalent products, from small molecules to complex biologics to combination products. Lachman's consultants are experienced and highly accurate in their recommendations so that your applications and submissions can have more rapid approvals.
Experts in 505(b)(2) submissions and ANDAs, Lachman Consultants works closely with sponsors in determining the most effective communication strategies and procedures regarding regulatory questions as well as the myriad of ways regulations affect submissions. Frances Zipp, Lachman Consultants' President and CEO, states, "The company also has the ability to act as U.S. agents and proactive partners to offshore entities, assisting them in communications and interactions with the U.S. Food and Drug Administration (FDA)."
MORE THAN FORTY YEARS OF ACHIEVEMENT
Since 1978, Lachman Consultants has furnished expert compliance, regulatory affairs, and technical services to clients around the world, helping to prevent and resolve compliance problems and assisting in the development of efficient and effective strategies for the submission and approval in the Pharmaceutical, Biotechnology, Biologics, Device and Related Industries.
Through its long-standing mastery of technical and regulatory consultation services, Lachman Consultants serves emerging-to-enterprise organizations across virtually every specialty of the life sciences. It is both expert and proficient in the development, implementation, and management of diversified projects involving scientific principles, technical challenges, and regulatory requirements.
QUALIFIED, RESPECTED AND REFERRED
The organization's multi-disciplinary team of accomplished FDA and industry experts collaborate extensively to ensure that problems entrusted to the firm are addressed from all angles, consistently delivering thoughtful, comprehensive and effective solutions.
Frances Zipp says, "Our highly experienced consultants have an extensive knowledge base, substantial resources, and the kind of wisdom that can only be acquired and developed through decades of experience."
A DYNAMIC NEW APPEARANCE
Lachman Consultants recently concluded its 40th anniversary with the development and introduction of a new logo, visual identity and message – "Experience. Excellence.TM" – a direct and dynamic expression of the organization's high standards for service, quality and client satisfaction. Frances Zipp adds, "Our new look and message are compelling expressions of our ongoing commitment to the support and advancement of the life sciences and the global community of valued clients we serve in close partnership."
SAY HELLO TO LACHMAN CONSULTANTS
Visitors to the Lachman Consultants Booths #21 and #26 at Access! 2019 will have the opportunity to visit with company executives and senior consultants to gain valuable knowledge about the company's services for generics and biosimilars and have their questions answered. On site will be Frances Zipp, President and CEO; Robert Pollock, Senior Advisor and Outside Director to the Board of Directors; Linda Evans O'Connor, Vice President, Chief of Staff; Aloka Srinivasan, Vice President Regulatory Practice; Keith Webber, Vice President, Biotechnology; and Michele Sinoway, Senior Manager, InfoServices.
# # # #
ABOUT LACHMAN CONSULTANTS
Founded in 1978, Lachman Consultants maintains three practice groups: Compliance, Regulatory Affairs and Science and Technology. Each practice offers industry-leading experience and expertise in its area of focus. Lachman Consultants serves emerging-to-enterprise organizations on a worldwide basis in the Pharmaceutical, Biotechnology, Biologics, Device and Related Life Science Industries. Lachman Consultants deliver solutions that include FDA-Related Services, Audits, Quality Assurance & Controls, Scientific and Technical Assistance, Systems Evaluation, Facilities Design or Validation System & Process Validation or Qualification and Training, which consistently exceed client requirements and expectations.
For additional press information, please contact:
Ilena Della Ventura
Delia Associates
T. 908-534-9044
E. [email protected]
SOURCE Lachman Consultants Services, Inc.
Share this article